Translating biology into medicine
The Translational Medicine Team forms the crucial bridge between drug discovery and the clinic. Understanding the potential impact of a medicine on patients requires specific skills. Our experts include physicians with a strong background in both biological research and clinical practice. Their dual experience helps them identify diseases which may be quite uncommon, but may actually provide an ideal proving ground for a new drug.
Proof of concept trials that give early insight
The Translational Medicine Group guides the design of Proof-of-Concept (PoC) clinical studies, which enable a quick assessment of a compound in a small number of patients against a known (and often rare) disease with a known molecular pathway. These clinical trials are designed to provide an early indication whether a new compound or biological drug can alter the disease pathway and have a therapeutic benefit for patients. Once we have a successful PoC study, the Novartis R&D strategy is to expand that benefit to people suffering from related diseases.
This approach is paying off. We now have a growing number of PoC compounds with indications ranging from hypertension to multiple sclerosis.
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar J, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang Y, Bertolino A, Gsteiger S, Wright A, Hueber W.
The Lancet, Volume 382, Issue 9906, 2013 Nov 23; Pages 1705 - 1713. doi: 10.1016/S0140-6736(13)61134-4
Safety, tolerability, and antibody response of active Aß immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo J, Graf A.
The Lancet Neurology, Volume 11, Issue 7, July 2012, Pages 597–604. DOI: 10.1016/S1474-4422(12)70140-0
Phase I, Open-Label, Single-Dose Study To Evaluate the Pharmacokinetics and Safety of Telbivudine in Children and Adolescents with Chronic Hepatitis B
Stein D, Ke J, Uy G, Bosheva M, Qi Y, Praestgaarda J for the LDT600A2104 Study Team
Antimicrob Agents Chemother. Sep 2013; 57(9): 4128–4133. doi: 10.1128/AAC.00117-13